Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, Placebo‐Controlled Trial

Citations Over TimeTop 10% of 2002 papers

Abstract

The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to prevent infection and disease in solid-organ transplant patients has not been evaluated by placebo-controlled trials. We carried out such a study in 69 patients who had received liver transplants and had positive results of CMV polymerase chain reaction within 8 weeks after transplantation but did not have concomitant CMV infection or disease. These patients were randomly assigned to receive placebo or oral ganciclovir for 8 weeks. CMV infection developed in 21% and disease developed in 12% of placebo recipients (P =.022), compared with 3% and 0%, respectively, among ganciclovir recipients (P =.003). Similarly, in the placebo arm, 55% and 36% of CMV-negative patients who received organs from CMV-positive donors developed CMV infection or disease, respectively (P =.02), compared with 11% and 0% of such patients in the ganciclovir arm (P <.01). Oral ganciclovir administered on CMV detection by PCR prevents CMV infection or disease after liver transplantation.

Related Papers

• → Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease(1995)49 cited
• → Synergistic Effect of 5-Nitro-2′-deoxyuridine with Ganciclovir Against Human CytomegalovirusIn Vitro(1995)9 cited
• [Ganciclovir treatment of congenital cytomegalovirus infection].(2006)
• Inhibitory effect of Ganciclovir on human cytomegalovirus in vitro(2010)
• Applied Indication of Ganciclovir in Human Cytomegalovirus-Related Idiopathic Thrombocytopenia Purpura(2006)